Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors effective May 27, 2026. Miller led R&D at Karuna through its $14 billion acquisition by Bristol Myers Squibb and was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia.
Key figures
- Karuna acquisition value
- $14 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.